Cullinan Therapeutics, Inc.
CGEM · NASDAQ · USD
$15.46
−0.17 −1.09%todayNot financial advice.
- Open
- 15.60
- Day range
- 14.81 - 15.71
- 52-week range
- 6.73 - 23.19
- Volume
- 1.14M
- Market cap
- 994.92M
- P/E ratio
- —
- EPS
- -3.39
- Dividend yield
- 0.00%
- Beta
- 1.02
Performance
W
+1.58%
1M
−28.46%
3M
−15.05%
6M
+1.44%
YTD
+46.82%
Y
+162.48%
5Y
−36.46%
All
−63.19%
In the news
Oct 8
Cullinan Therapeutics Doses First Patient in Phase 2 AML Study
Cullinan Therapeutics has dosed the first patient in a pivotal Phase 2 trial of CLN-049 for patients with relapsed or refractory acute myeloid leukemia.
Company news
Oct 8
Cullinan Therapeutics Starts Phase 2 Trial of Leukemia Candidate CLN-049
Cullinan Therapeutics has dosed the first patient in a Phase 2 trial of CLN-049 for relapsed or refractory acute myeloid leukemia.
Company news
Embed on your site
Embed docsAdd a live price card or a chart to any page. Free, no sign-up; cards refresh every minute and link back here.
<iframe src="https://stocks.freetheai.org/embed/NASDAQ-CGEM" width="340" height="170" style="border:0;max-width:100%" loading="lazy" title="Cullinan Therapeutics, Inc. (CGEM) - FreeTheAI Stocks"></iframe>
<p style="font-size:12px"><a href="https://stocks.freetheai.org/symbols/NASDAQ-CGEM">CGEM stock price</a> by FreeTheAI Stocks</p>